[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperactive-delirium\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperactive-delirium":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635115","phase-3-phenobarbital-for-agitated-delirium-100635115",false,"NCT07548489","Phenobarbital for Agitated Delirium","Inclusion Criteria:\n\n* Adult Patients identified by providers to have agitated or hyperactive delirium\n\nExclusion Criteria:\n\n* Pregnancy\n* Incarceration\n* Severe liver disease\n* Allergy or prior adverse reaction to phenobarbital or antipsychotic drugs (depending on the month of therapy initiation)","ALL","21 Years",{"count":18,"type":19},150,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","The goal of this clinical trial is to test whether the medication phenobarbital is as effective for treating agitated delirium among adult patients admitted to the intensive care unit. Agitated delirium is a condition involving confusion and impulsiveness which is dangerous to both patients and healthcare providers.\n\nThe main questions this trial aims to answer include:\n\n* Can phenobarbital decrease the amount of time patients with agitated delirium spend in the intensive care unit and the hospital?\n* Does phenobarbital decrease the amount of additional calming medications patients with agitated delirium need?\n\nResearchers in this study will compare phenobarbital to other medications commonly used to treat agitated delirium.\n\nParticipants will be monitored closely to make sure they remain safe and to measure how well their agitation and confusion are managed while they are in the ICU.",[25,26,27,28],"Agitated Delirium","Delirium Confusional State","Delirium in the Intensive Care Unit","Hyperactive Delirium","NOT_YET_RECRUITING","2026-04-17",{"date":32,"type":33},"2026-04-23","ACTUAL",{"date":35,"type":19},"2026-06",{"date":37,"type":19},"2027-07",{"name":39,"class":40},"Duke University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100425758","phase-1-effects-of-dexmedetomidine-in-patients-with-agitated-delirium-in-palliative-care-100425758","NCT04824144","Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care","Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care: an Open-label Phase 1\u002F2 Proof-of-concept, Feasibility, and Dose-finding Clinical Trial","Inclusion Criteria:\n\n1. Adult patients (≥18 years)\n2. Admitted to a participating inpatient palliative care unit\n3. Meeting one of the following criteria:\n\n   1. Agitated delirium: (i) Richmond Agitation-Sedation Scale for palliative care patients (RASS-PAL) score of +2 or greater and (ii) Confusion Assessment Method (CAM) positive status and (iii) Without a known potentially reversible cause (e.g. hypercalcemia, specific medication infection, etc.), or in whom the patient\u002FSubstitute Decision Maker (SDM) has requested not to treat the cause.\n   2. Previous history of delirium (in the last 6 months)\n   3. Patient is within the last two weeks of life and is expected to die during this admission (MRP judgement)\n\nExclusion Criteria:\n\n1. Hemodynamic instability (systolic blood pressure \\\u003C80mmHg)\n2. Bradyarrhythmia (heart rate \\\u003C 60) at baseline\n3. Patients on verapamil, diltiazem, or beta-blocker (patients are eligible if these medications are stopped prior to receiving dexmedetomidine)","18 Years",{"count":51,"type":19},50,[53,54],"PHASE1","PHASE2","The goal of this multi-centre phase I\u002FII open-label, single-arm study is to determine the feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated delirium among patients near the end of life followed by a palliative care provider in a non-monitored setting. Fifty patients will receive dexmedetomidine (0.4 mcg\u002Fkg\u002Fhour, titrated up to 1.0 mcg\u002Fkg\u002Fhour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be measured.",[28,57],"Delirium of Mixed Origin",[59,60,61,62,63],"Dexmedetomidine","Agitation","Delirium","Palliative","End of life","RECRUITING","2025-04-11",{"date":67,"type":33},"2025-04-15",{"date":69,"type":33},"2024-01-30",{"date":71,"type":19},"2026-03-31",{"name":73,"class":40},"Bruyère Health Research Institute.",3]